Teva's celiac antibody met Phase 2a goals, Allergic Living reports. Here's what the results mean for patients and families, and how far there is still to go.
Teva Pharmaceutical reports positive Phase 2a results for a celiac disease treatment, a welcome development in a pipeline that has seen repeated setbacks.
Takeda has cut a second phase 2 celiac therapy from its pipeline, leaving just one program. What the setback means for patients waiting on alternatives to the gluten-free diet.
Three new studies show how patient voices and real-world data are helping drug companies design better celiac disease trials and bring treatments closer to reality.
New research reveals how flawed screening criteria in celiac drug trials may cause them to fail—not because the drugs don't work, but because they're testing the wrong patients.
An experimental drug shows promise for treating celiac disease beyond the gluten-free diet. What celiac families should know about this development.
A major review outlines promising celiac disease treatments in development, from gluten-digesting enzymes to immune tolerance therapies.
The DAISY Study is recruiting adults with celiac disease who have symptoms despite a gluten-free diet. Travel compensation included.